The results of this study showed that MS patients in relapse, who clinically improved after iv methylprednisolone treatment (clinical responders), had significantly higher GILZ and MCL1 levels (more than twofold change) the first day of treatment. Here, TSC22D3 is linked to myeloid sarcoma.